MY183534A - Alkylpyrimidine derivatives for the treatment of viral infections and further diseases - Google Patents

Alkylpyrimidine derivatives for the treatment of viral infections and further diseases

Info

Publication number
MY183534A
MY183534A MYPI2015000167A MYPI2015000167A MY183534A MY 183534 A MY183534 A MY 183534A MY PI2015000167 A MYPI2015000167 A MY PI2015000167A MY PI2015000167 A MYPI2015000167 A MY PI2015000167A MY 183534 A MY183534 A MY 183534A
Authority
MY
Malaysia
Prior art keywords
treatment
viral infections
further diseases
alkylpyrimidine
derivatives
Prior art date
Application number
MYPI2015000167A
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Gowan David Craig Mc
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of MY183534A publication Critical patent/MY183534A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2015000167A 2012-08-10 2013-08-09 Alkylpyrimidine derivatives for the treatment of viral infections and further diseases MY183534A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12180167 2012-08-10
PCT/EP2013/066673 WO2014023813A1 (en) 2012-08-10 2013-08-09 Alkylpyrimidine derivatives for the treatment of viral infections and further diseases

Publications (1)

Publication Number Publication Date
MY183534A true MY183534A (en) 2021-02-25

Family

ID=48985736

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015000167A MY183534A (en) 2012-08-10 2013-08-09 Alkylpyrimidine derivatives for the treatment of viral infections and further diseases

Country Status (22)

Country Link
US (1) US9284304B2 (OSRAM)
EP (1) EP2882721B1 (OSRAM)
JP (1) JP6302906B2 (OSRAM)
KR (2) KR102216479B1 (OSRAM)
CN (2) CN104781239B (OSRAM)
AU (1) AU2013301450B2 (OSRAM)
BR (1) BR112015002524B1 (OSRAM)
CA (1) CA2879617C (OSRAM)
CL (1) CL2015000295A1 (OSRAM)
DK (1) DK2882721T3 (OSRAM)
EA (1) EA029266B1 (OSRAM)
ES (1) ES2707885T3 (OSRAM)
IL (1) IL236700A (OSRAM)
IN (1) IN2015MN00478A (OSRAM)
MX (1) MX369417B (OSRAM)
MY (1) MY183534A (OSRAM)
NZ (1) NZ703731A (OSRAM)
PH (1) PH12015500274B1 (OSRAM)
SG (1) SG11201500814UA (OSRAM)
UA (1) UA115558C2 (OSRAM)
WO (1) WO2014023813A1 (OSRAM)
ZA (1) ZA201500921B (OSRAM)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422250B2 (en) 2011-04-08 2016-08-23 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
JP6250046B2 (ja) 2012-07-13 2017-12-20 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症の処置のための大環状プリン
EA035327B1 (ru) 2012-10-10 2020-05-28 Янссен Сайенсиз Айрлэнд Юси Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
UA118341C2 (uk) 2012-11-16 2019-01-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Гетероциклічні заміщені похідні 2-амінохіназоліну для лікування вірусних інфекцій
EP2958900B1 (en) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidine derivatives for the treatment of viral infections
KR102280554B1 (ko) 2013-03-29 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염증의 치료를 위한 거대환식 데아자-퓨리논
JP6377139B2 (ja) 2013-05-24 2018-08-22 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体
CN105473592B (zh) 2013-06-27 2018-10-26 爱尔兰詹森科学公司 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
KR102322425B1 (ko) 2013-07-30 2021-11-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체
MY199988A (en) 2015-03-04 2023-12-02 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
CA2995004A1 (en) 2015-08-26 2017-03-02 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
EP3349757A1 (en) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
PE20181451A1 (es) 2015-12-15 2018-09-12 Gilead Sciences Inc Anticuerpos neutralizadores del virus de inmunodeficiencia humana
MA45088A (fr) 2016-05-27 2019-04-10 Gilead Sciences Inc Méthodes pour traiter des infections par le virus de l'hépatite b au moyen d'inhibiteurs de ns5a, ns5b ou ns3
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
CA3027471A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
DE102016212308B4 (de) 2016-07-06 2018-02-22 Thyssenkrupp Ag Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs, sowie Zahnstange
DE102016212307B4 (de) 2016-07-06 2018-02-22 Thyssenkrupp Ag Verfahren zur Herstellung einer Zahnstange für ein Kraftfahrzeug, sowie Zahnstange für ein Lenkgetriebe
DE102016212304B4 (de) 2016-07-06 2018-02-22 Thyssenkrupp Ag Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs, sowie Zahnstange
DE102016212303A1 (de) 2016-07-06 2018-01-11 Thyssenkrupp Ag Zahnstange und ein Verfahren zur Herstellung einer Zahnstange für ein Lenkgetriebe eines Kraftfahrzeugs
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3035346A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
JP7274415B2 (ja) 2016-09-29 2023-05-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ
MX2019004349A (es) 2016-10-14 2019-09-26 Prec Biosciences Inc Meganucleasas manipuladas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
US10662161B2 (en) 2017-01-30 2020-05-26 Regents Of The University Of Minnesota Pyrimidines and uses thereof
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
AR112412A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JP6934562B2 (ja) 2017-08-22 2021-09-15 ギリアード サイエンシーズ, インコーポレイテッド 治療用複素環式化合物
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CA3084667A1 (en) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
BR102019002873A2 (pt) 2018-02-13 2019-09-10 Gilead Sciences Inc inibidores de pd-1/pd-l1
EP3752495B1 (en) 2018-02-15 2023-07-19 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
ES2962605T3 (es) 2018-02-26 2024-03-20 Gilead Sciences Inc Compuestos de pirrolizina sustituidos como inhibidores de la replicación del VHB
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
LT4257600T (lt) 2018-07-03 2025-06-10 Gilead Sciences, Inc. Antikūnai, nukreipti į gp120, ir jų panaudojimo būdai
CA3103987C (en) 2018-07-06 2023-08-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
CN112384283B (zh) 2018-07-06 2023-08-15 吉利德科学公司 治疗性的杂环化合物
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
TWI842721B (zh) 2018-07-16 2024-05-21 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
JP2022500414A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
EP3873903B1 (en) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP7350872B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. 3’3’-環状ジヌクレオチドおよびそのプロドラッグ
KR102707808B1 (ko) 2019-03-07 2024-09-19 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
HUE059677T2 (hu) 2019-03-22 2022-12-28 Gilead Sciences Inc Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
CA3141085A1 (en) 2019-06-19 2020-12-24 Brenda Stevens Anti-mesothelin antibodies and immunoconjugates thereof
MY202182A (en) 2019-06-25 2024-04-15 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20250040096A (ko) 2019-09-30 2025-03-21 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CA3157275A1 (en) 2019-11-26 2021-06-03 Elena BEKERMAN Capsid inhibitors for the prevention of hiv
EP4567109A3 (en) 2019-12-06 2025-09-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン-4抗体コンジュゲートおよびその使用
TWI845826B (zh) 2020-03-20 2024-06-21 美商基利科學股份有限公司 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
PE20231304A1 (es) 2020-05-01 2023-08-24 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina inhibidores de cd73
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
AU2021320236B2 (en) 2020-08-07 2024-10-03 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20220144923A1 (en) 2020-11-11 2022-05-12 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
CN117203238A (zh) 2021-04-23 2023-12-08 普方生物制药美国公司 Cd70结合剂、其偶联物及其使用方法
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用FLT3L—Fc融合蛋白之方法
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリエルコール(diacylglyercol)キナーゼ調節化合物
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
AU2022403012A1 (en) 2021-12-03 2024-06-06 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202337439A (zh) 2021-12-03 2023-10-01 美商基利科學股份有限公司 用於hiv病毒感染之治療性化合物
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
JP2025522762A (ja) 2022-07-01 2025-07-17 ギリアード サイエンシーズ, インコーポレイテッド Cd73化合物
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
TW202444363A (zh) 2023-04-19 2024-11-16 美商基利科學股份有限公司 殼體抑制劑之給藥方案
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024281548A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250115680A1 (en) 2023-09-26 2025-04-10 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE283855T1 (de) 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
NZ504800A (en) 1997-11-28 2001-10-26 Sumitomo Pharma 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
DE69917469T2 (de) * 1998-08-27 2005-05-12 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidin derivate
US6583148B1 (en) * 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
CN101203519A (zh) 2005-05-04 2008-06-18 辉瑞有限公司 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2-酰氨基-6-氨基-8-氧代嘌呤衍生物
AU2008271127C1 (en) 2007-06-29 2014-04-17 Gilead Sciences, Inc. Purine derivatives and their use as modulators of Toll-like receptor 7
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists

Also Published As

Publication number Publication date
KR20210018974A (ko) 2021-02-18
KR102280589B1 (ko) 2021-07-22
UA115558C2 (uk) 2017-11-27
US9284304B2 (en) 2016-03-15
ZA201500921B (en) 2021-10-27
EP2882721A1 (en) 2015-06-17
MX369417B (es) 2019-11-07
DK2882721T3 (en) 2019-03-18
CN109232439A (zh) 2019-01-18
JP6302906B2 (ja) 2018-03-28
IL236700A (en) 2017-02-28
EA201590343A1 (ru) 2015-05-29
KR102216479B1 (ko) 2021-02-17
CL2015000295A1 (es) 2015-04-24
KR20150040910A (ko) 2015-04-15
IL236700A0 (en) 2015-02-26
AU2013301450A1 (en) 2015-02-05
WO2014023813A1 (en) 2014-02-13
NZ703731A (en) 2018-03-23
AU2013301450B2 (en) 2018-01-18
BR112015002524A2 (pt) 2017-07-04
PH12015500274A1 (en) 2015-04-27
ES2707885T3 (es) 2019-04-05
CN104781239B (zh) 2019-03-01
BR112015002524B1 (pt) 2021-11-03
IN2015MN00478A (OSRAM) 2015-09-04
SG11201500814UA (en) 2015-03-30
HK1207636A1 (en) 2016-02-05
JP2015524462A (ja) 2015-08-24
MX2015001829A (es) 2015-09-23
CN104781239A (zh) 2015-07-15
CA2879617C (en) 2021-05-04
EA029266B1 (ru) 2018-02-28
CA2879617A1 (en) 2014-02-13
US20150239872A1 (en) 2015-08-27
EP2882721B1 (en) 2018-12-05
PH12015500274B1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
PH12014501045B1 (en) Purine derivatives for the treatment of viral infections
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
PH12015502564A1 (en) Pyridone derivatives for the treatment of viral infections and further diseases